← Leaderboards
Cynthia X Ma
George Washington University
$3,639,182
Attributed
$8,888,820
Total exposure
6
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.7M · FY2017–25$5M$3.8M$2.5M$1.3M$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,888,820 · 6
By mechanism
R01$4,997,885 · 2
U24$2,556,953 · 1
U54$1,333,982 · 3
Top collaborators
- Kooresh Isaac Shoghi8 shared
- Shunqiang Li7 shared
- Farrokh Dehdashti4 shared
- Li Ding4 shared
- Wenge Zhu3 shared
Most similar at George Washington University
Same institution · by research overlap
- Elizabeth A Thom$177,996,531
- Rebecca Gersnoviez Clifton$95,055,095
- David I Watkins$75,196,434
- Michelle C Kegler$44,564,640
- John M Lachin$235,493,461
Others in their field
Other Emerging Leaders on “Response”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$195,683,539
- Kimberly Smith · Ppd Development Lp$115,671,664
- Paul F Gallagher · Woods Hole Oceanographic Institution$92,619,872
- Kevin Urdahl · Seattle Children'S Hospital$84,741,409
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,439,892
- Ted Ross · University Of Georgia$70,992,558
Research focus
ResponseTumorMalignant Breast NeoplasmBreast Cancer PatientBiological MarkersPredicting ResponseResistance MechanismTranscriptome SequencingResistanceClinical TrialsEstrogen Receptor PositivePharmaceutical PreparationsCombined Modality TherapyExome SequencingProteinsInhibitorGenetic SignatureMutationUniversitiesWashingtonBiopsyFuturePrediction Of Response To TherapyChemotherapy
Grant awards (19)
FFNP-PET as a predictive biomarker of response to endocrine therapy approaches in advanced breast cancer$1,254,028
R01 · FY2025 · CA
Washington University Co-Clinical Imaging Research Resource$645,323
U24 · FY2025 · CA
Regulation of resistance to CDK4/6 inhibitor in breast cancer$633,959
R01 · FY2025 · CA
Research Project 1$209,904
U54 · FY2025 · CA · contact PI
Washington University Co-Clinical Imaging Research Resource$613,057
U24 · FY2024 · CA
Regulation of resistance to CDK4/6 inhibitor in breast cancer$602,262
R01 · FY2024 · CA
FFNP-PET as a predictive biomarker of response to endocrine therapy approaches in advanced breast cancer$595,711
R01 · FY2024 · CA
Research Project 1$199,164
U54 · FY2024 · CA · contact PI
Regulation of resistance to CDK4/6 inhibitor in breast cancer$650,485
R01 · FY2023 · CA
Washington University Co-Clinical Imaging Research Resource$633,278
U24 · FY2023 · CA
FFNP-PET as a predictive biomarker of response to endocrine therapy approaches in advanced breast cancer$614,261
R01 · FY2023 · CA
Research Project 1$230,918
U54 · FY2023 · CA · contact PI
Washington University Co-Clinical Imaging Research Resource$665,295
U24 · FY2022 · CA
FFNP-PET as a predictive biomarker of response to endocrine therapy approaches in advanced breast cancer$647,179
R01 · FY2022 · CA
Research Project 1: Development of PI3K Inhibitors as Single Agents or in Combination with MEK Inhibitors for Breast Cancer$218,968
U54 · FY2019 · CA · contact PI
Research Project 1: Development of PI3K Inhibitors as Single Agents or in Combination with MEK Inhibitors for Breast Cancer$20,074
U54 · FY2019 · CA · contact PI
Research Project 1: Development of PI3K Inhibitors as Single Agents or in Combination with MEK Inhibitors for Breast Cancer$20,074
U54 · FY2019 · CA · contact PI
Research Project 1: Development of PI3K Inhibitors as Single Agents or in Combination with MEK Inhibitors for Breast Cancer$9,166
U54 · FY2019 · CA · contact PI
Research Project 1: Development of PI3K Inhibitors as Single Agents or in Combination with MEK Inhibitors for Breast Cancer$425,714
U54 · FY2017 · CA · contact PI